Replies to post #40534 on SurgLine International Inc (SGLN)

[Lighthouse]

Mexico, I like this post of yours, it is what most here need to read weekly, to pull them back from the edge....



"Been invested with CNUV/SGNL for a year now. Have taken the opportunity to load up on SGNL at these prices for the last 2 months.
I work in the medical sales field for the last 17 years I do see this PR as quite reassuring & positive going forward. In medical, contracts are not always up for renewal. SGNL has all the steps in place by working with national distributors that will have a choice to place SGNL products into their tenders. With very competitive pricing, we will see them winning some contracts & each win results in significant dollars.

These do not happen over night as trials & review committees are involved along with the timing of the contracts to be available to tender. This PR is trying to stress this & the fact that this is a bit of a different game that a majority of penny's.

This reassured me that we are on to something good but patience is needed."

Mexico

[LMPA]

http://www.sec.gov/cgi-bin/browse-edgar?company=surgline&match=&CIK=&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

[GOLDBUFFALO]

Just an amendment. Shows that SGLN remains current in reporting requirements. OTCQB! SGLN is gonna move up soon! I am buying monday at these low prices.

From the 10Q/A

SurgLine International, Inc. (the “Company”), formerly China Nuvo Solar Energy, Inc. is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment No. 1”) in response to comments received from the securities and Exchange Commission regarding the accounting treatment of the merger between SurgLine and China Nuvo to reflect the retroactive presentation required by reverse merger recapitalization accounting.

For ease of reference, this Amendment No. 1 amends the balances as of July 31, 2011 on the Shareholders’ Deficit Schedule to be retroactively restated for the equivalent number of shares issued to the accounting acquirer,SurgLine, with an adjustment to paid-in capital for any difference in par value. In addition, earnings or loss per share have been retroactively restated for the number of equivalent shares received by SurgLine, the accounting acquirer, as a result of the basic and dilutive weighted average shares outstanding have been restated to reflect the retroactive presentation of the shares recived by SurgLine.

Also, as required by Rule 12b-15 promulgated under the Securities Exchange Act of 1934, as amended, the Company's principal executive officer and principal financial officer have provided new Rule 13a-14(a) certifications and Section 1350 certifications in connection with this Amendment No. 1.